Sage Therapeutics - SAGE Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

13 analysts have issued twelve-month price targets for Sage Therapeutics' stock. Their SAGE share price forecasts range from $37.00 to $85.00. On average, they anticipate the company's share price to reach $50.73 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

Sage Therapeutics' stock was trading at $42.54 at the beginning of the year. Since then, SAGE stock has decreased by 7.2% and is now trading at $39.48.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SAGE earnings forecast.

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.84) by $0.37. The biopharmaceutical company earned $1.44 million during the quarter, compared to the consensus estimate of $2 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 32.76% and a negative net margin of 7,895.27%. During the same quarter in the previous year, the business earned ($2.03) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.11%), Vanguard Group Inc. (8.05%), Bellevue Group AG (4.99%), State Street Corp (4.97%), Price T Rowe Associates Inc. MD (3.60%) and Dimensional Fund Advisors LP (1.81%). Insiders that own company stock include Albert Robichaud, Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $39.48.

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.35 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis.

The company employs 471 workers across the globe.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.